248 related articles for article (PubMed ID: 30621698)
1. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Gavilá J; Oliveira M; Pascual T; Perez-Garcia J; Gonzàlez X; Canes J; Paré L; Calvo I; Ciruelos E; Muñoz M; Virizuela JA; Ruiz I; Andrés R; Perelló A; Martínez J; Morales S; Marín-Aguilera M; Martínez D; Quero JC; Llombart-Cussac A; Prat A
BMC Med; 2019 Jan; 17(1):8. PubMed ID: 30621698
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
3. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
4. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
7. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
Schneeweiss A; Möbus V; Tesch H; Hanusch C; Denkert C; Lübbe K; Huober J; Klare P; Kümmel S; Untch M; Kast K; Jackisch C; Thomalla J; Ingold-Heppner B; Blohmer JU; Rezai M; Frank M; Engels K; Rhiem K; Fasching PA; Nekljudova V; von Minckwitz G; Loibl S
Eur J Cancer; 2019 Jan; 106():181-192. PubMed ID: 30528802
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
[TBL] [Abstract][Full Text] [Related]
9. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.
Tuxen MK; Cold S; Tange UB; Balslev E; Nielsen DL
Acta Oncol; 2014 Oct; 53(10):1440-5. PubMed ID: 24991893
[No Abstract] [Full Text] [Related]
12. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer.
Gao JJ; Osgood CL; Gong Y; Zhang H; Bloomquist EW; Jiang X; Qiu J; Yu J; Song P; Rahman NA; Chiu HJ; Ricks TK; Rizvi F; Hou S; Wilson W; Abukhdeir AM; Seidman J; Ghosh S; Philip R; Pierce WF; Bhatnagar V; Kluetz PG; Pazdur R; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2021 Apr; 27(8):2126-2129. PubMed ID: 33188141
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
17. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.
Uriarte-Pinto M; Escolano-Pueyo Á; Gimeno-Ballester V; Pascual-Martínez O; Abad-Sazatornil MR; Agustín-Ferrández MJ
Int J Clin Pharm; 2016 Apr; 38(2):446-53. PubMed ID: 26951122
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA; Ensor JE; Creamer SL; Boone T; Rodriguez AA; Niravath PA; Darcourt JG; Meisel JL; Li X; Zhao J; Kuhn JG; Rosato RR; Qian W; Belcheva A; Schwartz MR; Kaklamani VG; Chang JC
Breast Cancer Res; 2019 Sep; 21(1):100. PubMed ID: 31477168
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]